Abeona Therapeutics Inc., a company specializing in cell and gene therapy using adeno-associated virus (AAV) technology, and Beacon Therapeutics, a Syncona-backed firm focusing on ophthalmic gene therapies, have announced a collaboration

HepaRegeniX GmbH, a clinical-stage company focused on developing innovative regenerative therapies for acute and chronic liver diseases, has successfully closed a Series C funding round, raising €15 million

Exscientia plc has recently announced an extended partnership with Amazon Web Services to enhance its drug discovery and automation platform using AWS's artificial intelligence

Rgenta Therapeutics, a biotechnology company specializing in developing oral small molecules that target RNA and RNA regulation for oncology and neurological disorders, has achieved a significant milestone

SciRhom GmbH has successfully concluded a EUR 63 million Series A financing round, co-led by Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington Partners

Alteogen Inc. has announced that the Ministry of Food and Drug Safety of Korea has granted approval for its New Drug Application for Tergase® (recombinant hyaluronidase). Developed using Alteogen's proprietary Hybrozyme™ Technology

Mirum Pharmaceuticals, Inc. has announced that the European Commission granted Marketing Authorization for LIVMARLI® oral solution, intended for treating progressive familial intrahepatic

BIOSENIC, a clinical-stage company specializing in severe autoimmune and inflammatory diseases and cell therapy, along with its subsidiary Medsenic SAS, has filed a continuation patent application US 18/763,376 with the United States

Roche announced today that the US Food and Drug Administration has approved the Vabysmo® 6.0 mg single-dose prefilled syringe for treating neovascular age-related macular degeneration, diabetic macular edema

Beacon Therapeutics, a prominent player in ophthalmic gene therapy focused on restoring vision in patients with severe retinal diseases, has successfully raised $170 million in Series B funding.